The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study
Status:
Completed
Trial end date:
2018-03-05
Target enrollment:
Participant gender:
Summary
This is a 14-day, randomized, placebo-controlled, parallel group, masked clinical trial of
oral guaifenesin for the therapy of Chronic Rhinitis (CRS) in 36 children between the ages of
7 and 18 years. The study investigates the effectiveness of guaifenesin in the relief of
nasal symptoms in children with CRS using the sinonasal 5 survey (SN-5) in comparison to
nasal airway volume, and biophysical properties of nasal secretion. The investigators
hypothesize that Guaifenesin use over a period of 14 days improves subjective nasal
complaints in pediatric patients with chronic rhinitis and nasal congestion, as measured by
the SN-5 survey compared to use of placebo. There will be an observed improvement in nasal
volume and cross-sectional area following use of guaifenesin, and nasal secretions will have
more favorable mucociliary and sneeze clearability compared to use of placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Virginia Commonwealth University
Collaborator:
Pfizer
Treatments:
Chlorpheniramine, phenylpropanolamine drug combination Guaifenesin Phenylpropanolamine